Comment on: Somatostatin receptor SPECT by Alicja Hubalewska-Dydejczyk et al.
LETTER TO THE EDITOR
Comment on Pepe et al.: Somatostatin receptor SPECT
Alicja Hubalewska-Dydejczyk & Anna Sowa-Staszczak &
Monika Tomaszuk
Received: 19 April 2012 /Accepted: 23 April 2012 /Published online: 30 May 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Dear Sir,
In a recent article, Pepe et al. presented a review of the
development of compounds for the study of somatostatin
receptors and their application in diagnostic imaging [1]. In
this very interesting paper the proven effectiveness of labelled
somatostatin analogues in the management of patients with
various somatostatin receptor-positive diseases is presented
(among others its role as a historical turn in the clinical
practice and diagnosis of gastroenteropancreatic neuroendo-
crine tumours, GEPNET). Althoughwe appreciate verymuch
this issue of the European Journal of Nuclear Medicine and
Molecular Imaging devoted to the most important aspects of
the usefulness of somatostatin analogues, we would like to
comment on some statements from the review by Pepe et al. In
this paper we read: “Given the importance and success of
99mTc as a routine isotope in nuclear medicine imaging, it
came as a logical consequence that 99mTc-labelled somatostat-
in analogues have been developed, namely the 99mTc-N-α-(6-
hydrazinonicotinoyl)-octreotide (99mTc-EDDA/HYNIC
OCT). At that time propagation of the tracer was hampered
by proprietary rights on the peptide. For this reason it has
remained a tracer for in-house use.”
To our knowledge 99mTc-EDDA/HYNIC-TOC is the ra-
diopharmaceutical most frequently used for the scintigraph-
ic visualization of sst-positive tumours in Poland. This
tracer was registered in Poland in 2004. It is also success-
fully used in many other European countries according to
their national regulations, so calling the availability of this
tracer “in-house use” only seems to be disappointing.
99mTc-Labelled radiopharmaceuticals, compared with for
example 111In-labelled compounds, may improve the quality
of images and radiation safety for patients and the staff as a
natural consequence of this isotope’s physical properties. As
it was stated in another review from this issue by Fani and
Maecke 99mTc is the “workhorse” in diagnostic nuclear
medicine not without a reason [2]. Also one could read there
about the labelling procedure of somatostatin analogues
with 99mTc, which may be evaluated as relatively cheap
and easily employed in any nuclear medicine hot lab, as
well as with high labelling yield and radiochemical purity of
the compound assured by the manufacturer and confirmed
in our experience.
It was shown that 99mTc-EDDA/HYNIC-TOC reveals
high in vitro and in vivo stability, fast background clearance,
relatively low accumulation in non-target tissues and rapid
detection of somatostatin receptor-positive tumours. Decris-
toforo et al. and Gabriel et al. studied the imaging abilities of
99mTc-EDDA/HYNIC-TOC compared to Octreoscan [3, 4].
The authors stated that 99mTc-EDDA/HYNIC-TOC was
characterized by higher tumour to normal tissue ratios than
Octreoscan. A higher target to non-target ratio was also
reported by Gabriel et al. for somatostatin receptor scintig-
raphy (SRS) with the use of 99mTc-N4-[Tyr
3]octreotate
(99mTc-Demotate) in comparison also to Octreoscan [5].
99mTc-EDDA/HYNIC-TOC revealed a higher sensitivity
for NET detection than Octreoscan (65.9 vs 51.2 %) [4].
More focal lesions were also detected, especially small liver
and lymph nodes metastases (125 vs 90 lesions). This fact
was probably related to four times higher 99mTc injected
activity in comparison to 111In as well as a higher receptor
affinity to 99mTc-labelled somatostatin analogues. In the
paper by Chrapko et al. [6] about daily clinical practice with
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the use of 99mTc-EDDA/HYNIC-TOC SRS, the authors
concluded that 99mTc-EDDA/HYNIC-TOC SRS is useful
in staging as well as in restaging after primary tumour
surgery of sst-positive tumours including tumours of
unknown primary origin.
Following 99mTc-EDDA/HYNIC-TOC, the Tyr3-octreo-
tate (TATE) somatostatin analogue was introduced. It is also
octreopeptide and differs from the Tyr3-octreotide (TOC) in
that the terminal threonine replaces threoninol. The terminal
threonine results in a higher receptor binding and better
internalization, with the consequence that tumour uptake
of the tracer is intense. In vitro studies revealed that TATE,
whether chelated with DTPA or DOTA, shows 14- to 17-
fold higher affinity to sst2 than octreotide and 8- to 10-fold
higher affinity than TOC. In studies performed by our group
the favourable pharmacokinetic parameters of this tracer
were shown [7]. Taking into account Polish experiences
with the use of 99mTc-EDDA/HYNIC-TATE, the focal
lesions were better visualized by this tracer than by Octreo-
scan. It seems to be connected with higher affinity of [Tyr3]
octreotate to sst2 and better special resolution due to 99mTc
physical properties. These results are consistent with the
outcomes of preclinical studies which indicated that [Tyr3]
octreotate radiotracers were characterized by the stated good
sst2 affinity and high degree of internalization of this
somatostatin analogue in tumour cells. Application of
99mTc-EDDA/HYNIC-TATE SRS followed by radio-
guided surgery (RGS) may significantly improve the rate
of detection and efficacy of treatment of NETs of the
gastrointestinal tract (GEP NET), especially in the pres-
ence of occult endocrine tumours. The imaging properties
of 99mTc-EDDA/HYNIC-TATE and possible 1-day imag-
ing protocol creates potential for more common applica-
tion of this tracer in oncology [8].
On the basis of available publications and Polish experi-
ences since 2004, it can be concluded that 99mTc-labelled
somatostatin analogues essentially improved diagnostic ef-
ficacy and contribute to optimization of the neuroendocrine
patients therapeutic procedure. The tracers are used for
localization of sst-positive tumours and their metastases
and above all as part of peptide receptor radionuclide ther-
apy (PRRT) (qualification to 90Y, 177Lu or 90Y/177Lu radio-
nuclide therapy and further control of therapy effectiveness)
and “cold” somatostatin analogue therapy. Although it is
expected that in future positron emission tomography (PET)
examinations with the use of somatostatin analogues la-
belled with 68Ga will replace any other forms of sst-
receptor positive tumour examinations, until then SRS with
the use of analogues labelled with 99mTc may be still con-
sidered a good alternative for the departments without PET
scanners. From our point of view, 99mTc-labelled somato-
statin analogues are important and effective members of the
radiolabelled peptide family.
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